Peanut Allergy Competitive Landscape Report 2018 - Market Insights, Epidemiology and Market Forecast to 2025 - ResearchAndMarkets.com

The "Peanut Allergy - Competitive Landscape, Market Insights, Epidemiology and Market Forecast 2025" drug pipelines has been added to ResearchAndMarkets.com's offering.

Peanut Allergy - Competitive Landscape, Market Insights, Epidemiology and Market Forecast 2025 provides comprehensive insights on the therapeutics development and the global market trends for the seven major markets i.e. United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The report covers the therapeutics market revenue, treatment practice and Peanut Allergy forecasted market share from 2017 to 2025, along with the global epidemiological forecast for this indication.

The reported prevalent cases of Peanut Allergy in 2015 were 6,719,025 in 7MM and estimated to increase in coming years. In certain European countries prevalence will decrease owing to the overall decrease in population. Currently there is no effective therapeutics or prophylactic products are available in market. The historical and current market size for this allergy comprises of Epinephrine and Anti-histamines. The first entry of Peanut Allergy treatment is expected in 2019 in US.

The report also includes therapeutic competitive landscape including 15+ pipeline products in this space. It further provides comparative pipeline analysis at various stages covering Phase III, Phase II, Phase I, Pre-clinical and Discovery. Active pipeline therapeutics assessment by stage, therapy type, route of administration and molecule type is also provided. Additionally, it also features the dormant and discontinued pipeline products. Leading companies in this space are Aimmune, DBV Technologies and AnaptysBio.

Key Topics Covered:

1. Peanut Allergy - Overview
2. Peanut Allergens
3. Symptoms
4. Clinical Symptoms
5. Risk Factors
6. Causes
7. Test and Diagnosis
8. Peanut Allergy Management and Treatment
9. Being prepared for a reaction
10. Prevalence
11. Scientific Research
12. Experimental Approaches
13. Sensitization
14. To Do/Not to Do
15. Epidemiology Overview - 7MM, 2015-2025
16. Comparative Analysis
17. Product Type
18. Late Stage Products (Phase III)
19. AR101: Aimmune Therapeutics
20. ANB020: AnaptysBio
21. SAR-439794: Sanofi
22. SVP-CPE + SVP-Resiquimod: Selecta Biosciences
23. Assessment by Route of Administration
24. Assessment by Stage and Route of Administration
25. Assessment by Molecule Type
26. Assessment by Stage and Molecule Type
27. Dormant and Discontinued Products
28. Comparative Analysis
29. Market Assessment: 7MM
30. Appendix

Companies Mentioned

• Aimmune
• Allergy Therapeutics
• AnaptysBio
• ASIT biotech
• BioLingus
• DBV Technologies
• Genentech
• Laboratorios LETI
• Prota Therapeutics
• Selecta Biosciences
• Virtici

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/fzflbs/peanut_allergy?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20181203005354/en/